A Study of the Safety of Atezolizumab in Participants With Locally Advanced or Metastatic Non Small Cell Lung Cancer in Argentina

Hoffmann-La Roche44 enrolled

Overview

This is a study of the safety and effectiveness of atezolizumab in participants with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Participants also will have progressed on an appropriate approved targeted therapy if their tumor has epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) gene abnormalities treated in common clinical practice settings in Argentina.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Carcinoma, Non-small-cell Lung

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Signed an informed consent form submitted to the Administración Nacional de Medicamentos Alimentos y Tecnología Médica (ANMAT) * Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) non-small cell lung cancer (NSCLC) * Have received at least one dose of atezolizumab as per local label and clinical practice Exclusion Criteria: * Contraindicated atezolizumab therapy

Locations (1)

Productos Roche S.A. Quimica e Industrial, División Farmacéutica

Buenos Aires, Argentina